Vendor comparison · 2026
ARA-290 vendors: 18 compared on COAs and price
Tissue & recoveryAlso known as Cibinetide, pHBSP
Evidence tier
Regulator-reviewed human evidence
2 human trials · 2 reviews
- Vendors carrying it
- 18
- 16 with a listed price
- Vendors with checkable COAs
- 8
- 8 publish any certificate
- Lots tested
- 8
- 8 naming a checkable lab
- Independent assays
- 0
- none on file yet
- Newest assay
- 24 Sept 2026
- oldest 24 Feb 2026
- Laboratories named
- 5
- most often Freedom Diagnostics Testing
- Median label gap
- 5.2%
- 50% of lots within 5% of label
- Median purity
- 99.72%
- 8 of 8 lots at 99% or above
- Lowest price per mg
- $4.00
- peer median $5.50
- Publications located
- 60
- researched since 2012
Source: PepIndex, an independent index of research-peptide vendors. No vendor can pay for a rank, every score is computed by a published formula, and every figure links to the document it was read from.
Next Gen Peptides has the most checkable ARA-290 testing in this index: 1 lot assayed by ILS Laboratories, the newest on 24 Aug 2026. The lowest listed price is $4.00 per mg at Good Science Bio, against a peer median of $5.50. 18 vendors carrying ARA-290 are compared below. 8 publish at least one certificate naming a checkable laboratory, 8 lot records are on file, and none is an independently commissioned assay. Figures are PepIndex's own: it is an independent index of research-peptide vendors, no vendor can pay for a rank, and each figure links to the certificate it was read from.
Every vendor carrying ARA-290
| # | Vendor | Score here | Price / mg | Lots | Newest test | Laboratory | Mean purity | Label gap | Reports |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Next Gen PeptidesISO/IEC 17025 | 93.697% | — | 1 / 1 | ILS Laboratories | 99.6% | 3.7% | ||
| 2 | Ascend ScienceISO/IEC 17025 | 88.694% | $4.90 (89%) | 0 | — | — | — | — | |
| 3 | Amino ClubISO/IEC 17025Age-gated COAs | 87.398% | $5.00 (91%) | 0 | — | — | — | — | |
| 4 | PeptidePlugs | 86.194% | $5.00 (91%) | 1 / 1 | Freedom Diagnostics Testing | 99.8% | 4.3% | ||
| 5 | Hydro Research PeptidesISO/IEC 17025 | 83.989% | — | 1 / 1 | ILS Laboratories | 99.9% | 2.8% | ||
| 6 | Bench Grade Peptides | 82.589% | $5.00 (91%) | 1 / 1 | Freedom Diagnostics Testing | 99.3% | 6.6% | ||
| 7 | One Aminos | 81.889% | $5.50 (100%) | 1 / 1 | United Laboratories | 99.4% | 6.2% | ||
| 8 | Protide HealthAge-gated COAs | 79.992% | $5.00 (91%) | 0 | — | — | — | — | no reportVisit site |
| 9 | Ascension Peptides | 75.989% | $7.00 (127%) | 1 / 1 | MZ Biolabs | 99.9% | 0.1% | ||
| 10 | Good Science Bio | 7371% | $4.00 (73%) | 0 | — | — | — | — | no reportVisit site |
| 11 | Northline LabsISO/IEC 17025 | 72.495% | $8.00 (146%) | 0 | — | — | — | — | no reportVisit site |
| 12 | Licensed Peptides | 7287% | $5.94 (108%) | 0 | — | — | — | — | no reportVisit site |
| 13 | Simple Peptide | 71.592% | $7.60 (138%) | 1 / 1 | Freedom Diagnostics Testing | 99.3% | 6.6% | ||
| 14 | Modern AminosISO/IEC 17025COAs need an account | 67.997% | $10.20 (186%) | 1 / 1 | Vanguard Laboratory | 99.9% | 17.0% | ||
| 15 | NeuroLabs Research | 67.891% | $9.79 (178%) | 0 | — | — | — | — | no reportVisit site |
| 16 | BioLongevity Labs | 64.572% | $6.33 (115%) | 0 | — | — | — | — | no reportVisit site |
| 17 | Mile High Compounds | 62.391% | $5.00 (91%) | 0 | — | — | — | — | no reportVisit site |
| 18 | Biotech Peptides | 62.160% | $5.50 (100%) | 0 | — | — | — | — | no reportVisit site |
Independent assays
No independently commissioned assay of ARA-290 is on file. All 8 records below were published by the vendor that sells the product, naming the laboratory shown. PepIndex does not yet commission its own assays, so nothing on this page establishes what is in a vial beyond the vendor’s own certificate. A record moves into this section the moment an assay commissioned by anyone other than the seller is indexed.
What the certificates show
8 of 8 lots at 99% or above; median 99.72%.
| Range | lots |
|---|---|
| <95% | 0 |
| 95–97% | 0 |
| 97–98% | 0 |
| 98–99% | 0 |
| 99–99.5% | 3 |
| ≥99.5% | 5 |
50% of lots within 5% of the labelled mass; median gap 5.2%.
| Range | lots |
|---|---|
| ≤2% | 1 |
| 2–5% | 3 |
| 5–10% | 3 |
| 10–20% | 1 |
| >20% | 0 |
16 vendors, $4.00 to $10.20; median $5.50.
| Range | vendors |
|---|---|
| $4.00–$6.00 | 10 |
| $6.00–$8.00 | 3 |
| $8.00–$10.00 | 2 |
| $10.00–$12.00 | 1 |
Purity and mass are read from each certificate as published; the label gap is |labeled − assayed| ÷ labeled. Every value behind these bars is in the certificate table below.
Laboratories used
| Laboratory | Lots | Vendors | Share | Verify |
|---|---|---|---|---|
| Freedom Diagnostics TestingUS | 3 | 3 | 38% | Public lookup |
| ILS LaboratoriesUS | 2 | 2 | 25% | Public lookup |
| MZ BiolabsUS | 1 | 1 | 13% | No public lookup found |
| United LaboratoriesIN | 1 | 1 | 13% | Public lookup |
| Vanguard LaboratoryUS | 1 | 1 | 13% | No public lookup found |
Every certificate record
| Vendor | Lot | Tested | Lab | Labeled | Assayed | Discrepancy | Purity | Report |
|---|---|---|---|---|---|---|---|---|
 Hydro Research Peptides | HR-2026-1256 | ILS Laboratories | 10 mg | 10.28 mg | 2.8% | 99.9% | Vendor-published | |
 One Aminos | ONE-ARA10-091426 | United Laboratories | 10 mg | 10.62 mg | 6.2% | 99.4% | Vendor-published | |
 Next Gen Peptides | ARA16-01 | ILS Laboratories | 16 mg | 16.59 mg | 3.7% | 99.6% | Vendor-published | |
 Modern Aminos | BX-P-D7N6 | Vanguard Laboratory | 10 mg | 11.7 mg | 17.0% | 99.9% | Vendor-published | |
 PeptidePlugs | 142-01-DK | Freedom Diagnostics Testing | 10 mg | 10.43 mg | 4.3% | 99.8% | Vendor-published | |
 Bench Grade Peptides | ARA16-052026-7 | Freedom Diagnostics Testing | 16 mg | 17.05 mg | 6.6% | 99.3% | Vendor-published | |
 Simple Peptide | ARA16-052026-7 | Freedom Diagnostics Testing | 16 mg | 17.05 mg | 6.6% | 99.3% | Vendor-published | |
 Ascension Peptides | 53-12250129 | MZ Biolabs | 10 mg | 9.99 mg | 0.1% | 99.9% | Vendor-published |
Score breakdown
The score has two halves: the research base — how long the compound has been studied and how much has been published — and the quality of the evidence the market produces for it, aggregated across every vendor that carries it: assayed purity, lot-to-lot consistency, readable third-party certificates and those vendors’ review record. It measures the evidence base, not the merits or safety of the substance.
Studied since 2012 — 14 years of published research
How long the compound has been studied. Fifteen years or more of published literature earns full marks; a newer compound earns less.
60 publications indexed in PubMed
The volume of published literature located. Full marks at fifty or more publications.
Mean assayed purity 99.6% across 8 certificates
Average assayed purity on the certificates published by vendors that carry this compound. Full marks at 99.5%+, nothing at 95% or below.
±0.27 pts purity across lots, mean label deviation 5.9%
How tightly assayed purity and labeled-versus-actual mass hold across different lots. Rewards reproducible manufacturing.
18 of 18 listing vendors publish an accessible certificate policy
Whether the vendors carrying this compound publish per-lot certificates anyone can read without an account.
8 of 8 certificates from a recognised independent lab
Share of certificates issued by a recognised third-party testing lab rather than an unnamed or self-named one.
What is ARA-290?
An eleven–amino-acid peptide derived from the structure of erythropoietin, designed to engage tissue-protective signalling without the red-blood-cell effects of erythropoietin.
Studied in published research for neuropathic pain and tissue protection.
Regulatory status
Labeled by vendors for laboratory research use only. Not approved as a medicine in the United States, United Kingdom, or European Union.
What the research examines
The areas of published research this compound appears in. These describe what the literature has studied — never a claim of benefit, effect or suitability for any use.
Published research
Investigated in human trials for neuropathic conditions such as sarcoidosis-associated small-fibre neuropathy. PepIndex does not evaluate clinical significance and does not describe administration.
- Editorial — Molecular medicine (Cambridge, Mass.) (2013)
Peer-reviewed article indexed in PubMed, published in Molecular medicine (Cambridge, Mass.) (2013).
- ARA 290 for treatment of small fiber neuropathy in sarcoidosis — Expert opinion on investigational drugs (2014)
Peer-reviewed article indexed in PubMed, published in Expert opinion on investigational drugs (2014).
- The time to develop treatments for diabetic neuropathy — Expert opinion on investigational drugs (2021)
Peer-reviewed article indexed in PubMed, published in Expert opinion on investigational drugs (2021).
- Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression — Brain, behavior, and immunity (2022)
Peer-reviewed article indexed in PubMed, published in Brain, behavior, and immunity (2022).
- ARA 290 relieves pathophysiological pain by targeting TRPV1 channel: Integration between immune system and nociception — Peptides (2016)
Peer-reviewed article indexed in PubMed, published in Peptides (2016).
- A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema — Journal of clinical medicine (2020)
Peer-reviewed article indexed in PubMed, published in Journal of clinical medicine (2020).
- Cibinetide dampens innate immune cell functions thus ameliorating the course of experimental colitis — Scientific reports (2017)
Peer-reviewed article indexed in PubMed, published in Scientific reports (2017).
- Improvement of Islet Allograft Function Using Cibinetide, an Innate Repair Receptor Ligand — Transplantation (2020)
Peer-reviewed article indexed in PubMed, published in Transplantation (2020).
Indexed studies4 human-evidence of 4
- Managing fatigue in sarcoidosis - A systematic review of the evidence — Systematic review, 2017
Fatigue is a common manifestation of sarcoidosis, often persisting without evidence of disease activity. First-line therapies for sarcoidosis have limited effect on fatigue. This review aimed to assess the treatment options targeting sarcoidosis-associated fatigue. Medline and Web of Science were searched in November 2015; the bibliographies of these papers, and relevant review papers, were also searched. Studies were included if they reported on the efficacy of interventions…
- The time to develop treatments for diabetic neuropathy — Systematic review, 2021
Diabetic neuropathy is a multifaceted condition affecting up to 50% of individuals with long standing diabetes. The most common presentation is peripheral diabetic sensory neuropathy (DPN). We carried out a systematic review of papers dealing with diabetic neuropathy on Pubmed in addition to a targeted Google search.Search terms included small fiber neuropathy,diffuse peripheral neuropathy, quantitative sensory testing, nerve conduction testing, intra-epidermal nerve fiber de…
- Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study — Human — controlled trial, 2012
ARA 290 (a peptide designed to activate the innate repair receptor that arrests injury and initiates cytoprotection, antiinflammation and healing) reduces allodynia in preclinical neuropathy models. We studied the safety and efficacy of ARA 290 to reduce symptoms of small fiber neuropathy (SFN) in patients with sarcoidosis. A total of 22 patients diagnosed with sarcoidosis and symptoms of SFN were enrolled in a double-blind, placebo-controlled exploratory trial consisting of …
- Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain — Human — controlled trial, 2017
Sarcoidosis frequently is complicated by small nerve fiber loss (SNFL), which can be quantified using corneal confocal microscopy (CCM). Prior studies suggest that the innate repair receptor agonist cibinetide reverses corneal nerve loss. This phase 2b, 28-day, randomized trial of 64 subjects with sarcoid-associated SNFL and neuropathic pain assessed the effect of cibinetide on corneal nerve fiber area (CNFA) and regenerating intraepidermal fibers (GAP-43+) as surrogate endpo…
Evidence digest
What the research on ARA-290 actually shows
The indexed literature on ARA-290 includes human clinical or observational records (4 human-clinical or observational records). This digest describes the shape of that evidence and links the records behind it. It does not judge whether ARA-290 is safe or effective for any purpose, and nothing here is medical advice — the material sold by the vendors in this index is labeled for laboratory research use only.
3 things the literature does not establish →
PepIndex describes what literature exists. We do not interpret it, assess clinical significance, or publish quantities, protocols or instructions for use.